

Special Issue

Precision Oncology in Solid Tumors: Emerging Biomarkers and Therapeutic Targets

Message from the Guest Editor

This Special Issue aims to highlight recent breakthroughs and remaining challenges in the identification and clinical implementation of predictive and prognostic biomarkers across major solid tumors. Topics will include the integration of next-generation sequencing, liquid biopsy, and spatial multi-omics for comprehensive tumor characterization; the development of novel therapeutic targets and immune regulation; and the role of artificial intelligence and digital pathology in refining diagnostic precision. Attention will also be given to mechanisms of therapeutic resistance, tumor microenvironment modulation, and innovative combination strategies involving immunotherapy, antibody-drug conjugates, and epigenetic drugs. By bringing together contributions from pathologists, oncologists, and translational scientists, this Special Issue seeks to provide a multidisciplinary overview of how molecular insights are reshaping cancer care. Ultimately, the goal is to bridge the gap between laboratory discoveries and clinical application, fostering a more individualized, data-driven approach to cancer diagnosis and treatment.

Guest Editor

Dr. Giuseppe Nicolò Fanelli

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA

Deadline for manuscript submissions

30 June 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/258540

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).